ObesityWeek® 2026, The Obesity Society’s 44th Annual Meeting, will take place in Washington, DC, from November 14–17, 2026. Researchers, clinicians and patient advocates from around the world will come together to share advances in obesity research, clinical care and public health.
MindRank will present clinical results for MDR-001, our AI-enabled oral small-molecule GLP-1 receptor agonist, in adults with overweight or obesity.
MDR-001 is currently in Phase III clinical development in China for obesity and related metabolic conditions. The poster will report 12-week weight-loss results and safety observations with once-daily (QD) oral dosing. Its efficacy and safety will continue to be evaluated in ongoing and future clinical studies.
As an oral small-molecule candidate, MDR-001 does not require injections and may make long-term treatment more convenient. Its oral formulation may also offer practical advantages in manufacturing, storage and distribution.
Poster Presentation Details：
Title:MDR-001, an AI-Enabled, Once-Daily GLP-1RA in Adults With Overweight or Obesity at Week 12
Presenter：Colin Lin, CBO of MindRank
Session:Clinical Trials: Efficacy, Safety & Weight-Loss Outcomes
Poster Number: Poster-419
Date and Time:Sunday, November 15, 2026, 2:30–3:30 p.m. (EST)
Location:Gaylord National Resort & Convention Center Exhibit Hall BCD
We invite researchers, clinicians and potential partners to visit Poster-419 to discuss MDR-001’s clinical development, the role of AI-enabled drug discovery in obesity treatment and opportunities for collaboration.
About MDR-001
MDR-001 is discovered and developed using MindRank's proprietary AI-native R&D engine, Molecule Arts Platform (MAP). The drug candidate moved from initiation to Phase III in only 4.5 years, with an R&D spend of $23 million, putting a spotlight on MAP's potential to dramatically lower drug development cost versus traditional approaches.
In the completed 24-week Phase IIb clinical trial, mean body weight reductions from baseline ranged from 8.2% to 10.3% across the MDR-001 dose groups, compared with 2.5% in the placebo group. The proportion of participants achieving at least 10% weight loss ranged from 34.5% to 48.1% across the MDR-001 dose groups. The rate of treatment discontinuation due to adverse events was 0.8%, while improvements in certain metabolic parameters were also observed. The efficacy and safety of MDR-001 will be further evaluated in subsequent clinical studies.
About MindRank
MindRank is a leading clinical-stage, AI-native biotechnology company dedicated to advancing innovative drug discovery and development through machine learning, reinforcement learning and first-principles calculations. Its proprietary, integrated AI platform brings together biology, structural biology, chemistry and medicine to push the boundaries of pharmaceutical innovation, develop treatments for more diseases and help more people regain their health.